Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Prognostic value of a new clinically-based classification system in patients with CMML undergoing allogeneic HCT: a retrospective analysis of the EBMT-CMWP

F. Onida, G. Sbianchi, A. Radujkovic, K. Sockel, N. Kröger, J. Sierra, G. Socié, J. Cornelissen, X. Poiré, L. Raida, JH. Bourhis, J. Finke, J. Passweg, U. Salmenniemi, HC. Schouten, Y. Beguin, S. Martin, E. Deconinck, A. Ganser, S. Zver, B....

. 2022 ; 57 (6) : 896-902. [pub] 20220329

Language English Country Great Britain

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc22018108
E-resources Online Full text

NLK Free Medical Journals from 1997 to 1 year ago
Freely Accessible Science Journals from 1997 to 1 year ago
ProQuest Central from 2000-01-01 to 1 year ago
Open Access Digital Library from 1997-01-01
Health & Medicine (ProQuest) from 2000-01-01 to 1 year ago

Links

PubMed 35352038
DOI 10.1038/s41409-021-01555-9
Knihovny.cz E-resources

Recently a new three-group clinical classification was reported by an International Consortium to stratify CMML patients with regard to prognosis. The groups were defined as follows: (1) Myelodysplastic (MD)-CMML: WBC ≤ 10 × 109/l, circulating immature myeloid cells (IMC) = 0, no splenomegaly; (2) MD/MP (overlap)-CMML: WBC 10-20 × 109/l or WBC ≤ 10 × 109/l but IMC > 0 and/or splenomegaly; (3) Myeloproliferative (MP)-CMML: WBC > 20 × 109/l. By analysing EBMT Registry patients who underwent allo-HCT for CMML between 1997 and 2016, we aimed to determine the impact of this classification on transplantation outcome and to make a comparison with the conventional WHO classification (CMML-0/CMML-1/CMML-2). Patient grouping was based on the data registered at time of transplantation, with IMC replaced by peripheral blasts. Among 151 patients included in the analysis, 38% were classified as MD-CMML, 42% as MD/MP-CMML and 20% as MP-CMML. With a median survival of 17 months in the whole series, MD-CMML patients were distinguished as a low-risk group with higher CR rate at transplant and a longer post-transplant 2-year progression-free survival in comparison to others (44.5% vs 33.5%, respectively), whereas the WHO classification was superior in identifying high-risk patients (CMML-2) with inferior survival outcomes.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22018108
003      
CZ-PrNML
005      
20220804134548.0
007      
ta
008      
220720s2022 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1038/s41409-021-01555-9 $2 doi
035    __
$a (PubMed)35352038
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Onida, Francesco $u Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico-University of Milan, Milan, Italy. francesco.onida@unimi.it $1 https://orcid.org/0000000229913474
245    10
$a Prognostic value of a new clinically-based classification system in patients with CMML undergoing allogeneic HCT: a retrospective analysis of the EBMT-CMWP / $c F. Onida, G. Sbianchi, A. Radujkovic, K. Sockel, N. Kröger, J. Sierra, G. Socié, J. Cornelissen, X. Poiré, L. Raida, JH. Bourhis, J. Finke, J. Passweg, U. Salmenniemi, HC. Schouten, Y. Beguin, S. Martin, E. Deconinck, A. Ganser, S. Zver, B. Lioure, R. Rohini, L. Koster, P. Hayden, S. Iacobelli, M. Robin, I. Yakoub-Agha
520    9_
$a Recently a new three-group clinical classification was reported by an International Consortium to stratify CMML patients with regard to prognosis. The groups were defined as follows: (1) Myelodysplastic (MD)-CMML: WBC ≤ 10 × 109/l, circulating immature myeloid cells (IMC) = 0, no splenomegaly; (2) MD/MP (overlap)-CMML: WBC 10-20 × 109/l or WBC ≤ 10 × 109/l but IMC > 0 and/or splenomegaly; (3) Myeloproliferative (MP)-CMML: WBC > 20 × 109/l. By analysing EBMT Registry patients who underwent allo-HCT for CMML between 1997 and 2016, we aimed to determine the impact of this classification on transplantation outcome and to make a comparison with the conventional WHO classification (CMML-0/CMML-1/CMML-2). Patient grouping was based on the data registered at time of transplantation, with IMC replaced by peripheral blasts. Among 151 patients included in the analysis, 38% were classified as MD-CMML, 42% as MD/MP-CMML and 20% as MP-CMML. With a median survival of 17 months in the whole series, MD-CMML patients were distinguished as a low-risk group with higher CR rate at transplant and a longer post-transplant 2-year progression-free survival in comparison to others (44.5% vs 33.5%, respectively), whereas the WHO classification was superior in identifying high-risk patients (CMML-2) with inferior survival outcomes.
650    12
$a transplantace hematopoetických kmenových buněk $7 D018380
650    _2
$a lidé $7 D006801
650    12
$a chronická myelomonocytární leukemie $7 D015477
650    _2
$a prognóza $7 D011379
650    _2
$a retrospektivní studie $7 D012189
655    _2
$a časopisecké články $7 D016428
700    1_
$a Sbianchi, Giulia $u Department of Biology, Tor Vergata University, Rome, Italy
700    1_
$a Radujkovic, Aleksandar $u University of Heidelberg, Heidelberg, Germany $1 https://orcid.org/0000000285435016
700    1_
$a Sockel, Katja $u University Hospital Dresden, TU Dresden, Dresden, Germany
700    1_
$a Kröger, Nicolaus $u University Hospital Eppendorf, Hamburg, Germany
700    1_
$a Sierra, Jorge $u Hospital Santa Creu i Sant Pau, Barcelona, Spain $1 https://orcid.org/0000000279660356
700    1_
$a Socié, Gerard $u Hospital St. Louis, Paris, France $1 https://orcid.org/0000000221147533
700    1_
$a Cornelissen, Jan $u Erasmus MC Cancer Institute, Rotterdam, The Netherlands
700    1_
$a Poiré, Xavier $u Cliniques Universitaires St. Luc, Brussels, Belgium $1 https://orcid.org/0000000318970227
700    1_
$a Raida, Luděk $u Department of Hemato-Oncology-Faculty Hospital Olomouc and Faculty of Medicine and Dentistry, Palacký University, Olomouc, Czech Republic
700    1_
$a Bourhis, Jean Henri $u Gustave Roussy, Institut de Cancérologie, Val-de-Marne, Villejuif, France
700    1_
$a Finke, Jürgen $u University of Freiburg, Freiburg, Germany
700    1_
$a Passweg, Jakob $u University Hospital, Basel, Basel, Switzerland
700    1_
$a Salmenniemi, Urpu $u Turku University Hospital, Turku, Finland
700    1_
$a Schouten, Harry C $u University Hospital Maastricht, Maastricht, The Netherlands
700    1_
$a Beguin, Yves $u CHU of Liege and University of Liege, Liege, Belgium
700    1_
$a Martin, Sonja $u Robert-Bosch-Krankenhaus, Stuttgart, Germany $1 https://orcid.org/0000000181816834
700    1_
$a Deconinck, Eric $u Hospital Jean Minjoz, Besancon, France
700    1_
$a Ganser, Arnold $u Hannover Medical School, Hannover, Germany
700    1_
$a Zver, Samo $u University Medical Center, Ljubljana, Slovenia $1 https://orcid.org/0000000329327923
700    1_
$a Lioure, Bruno $u Nouvel Hopital Civil, Strasbourg, France
700    1_
$a Rohini, Radia $u Nottingham University, Nottingham, UK
700    1_
$a Koster, Linda $u EBMT Data Office Leiden, Leiden, The Netherlands
700    1_
$a Hayden, Patrick $u Department of Haematology, Trinity College Dublin, St. James's Hospital, Dublin 8, Ireland $1 https://orcid.org/0000000313744503
700    1_
$a Iacobelli, Simona $u Department of Biology, Tor Vergata University, Rome, Italy
700    1_
$a Robin, Marie $u Hospital St. Louis, Paris, France $1 https://orcid.org/0000000313889876
700    1_
$a Yakoub-Agha, Ibrahim $u CHU de Lille, Univ Lille, Infinite, INSERM U1286, 59000, Lille, France $1 https://orcid.org/0000000345248782
773    0_
$w MED00000834 $t Bone marrow transplantation $x 1476-5365 $g Roč. 57, č. 6 (2022), s. 896-902
856    41
$u https://pubmed.ncbi.nlm.nih.gov/35352038 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220720 $b ABA008
991    __
$a 20220804134542 $b ABA008
999    __
$a ok $b bmc $g 1821938 $s 1169351
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2022 $b 57 $c 6 $d 896-902 $e 20220329 $i 1476-5365 $m Bone marrow transplantation $n Bone Marrow Transplant $x MED00000834
LZP    __
$a Pubmed-20220720

Find record

Citation metrics

Archiving options